Evolent Health, Inc. (NYSE:EVH) Stock Position Lifted by Mesirow Institutional Investment Management Inc.

Mesirow Institutional Investment Management Inc. grew its stake in shares of Evolent Health, Inc. (NYSE:EVH - Free Report) by 67.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 701,927 shares of the technology company's stock after buying an additional 282,509 shares during the period. Mesirow Institutional Investment Management Inc. owned approximately 0.60% of Evolent Health worth $7,897,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Pilgrim Partners Asia Pte Ltd bought a new stake in shares of Evolent Health in the fourth quarter valued at about $26,000. R Squared Ltd bought a new position in shares of Evolent Health in the fourth quarter valued at $31,000. AlphaQuest LLC increased its stake in shares of Evolent Health by 21,650.0% during the 4th quarter. AlphaQuest LLC now owns 3,045 shares of the technology company's stock worth $34,000 after purchasing an additional 3,031 shares during the last quarter. Parkside Financial Bank & Trust grew its holdings in Evolent Health by 90.7% during the fourth quarter. Parkside Financial Bank & Trust now owns 4,957 shares of the technology company's stock worth $56,000 after purchasing an additional 2,358 shares during the period. Finally, AlphaCentric Advisors LLC acquired a new stake in shares of Evolent Health in the fourth quarter valued at approximately $61,000.

Evolent Health Price Performance

Shares of Evolent Health stock traded down $0.21 on Friday, reaching $8.89. The company's stock had a trading volume of 1,034,838 shares, compared to its average volume of 2,335,408. Evolent Health, Inc. has a 52-week low of $8.35 and a 52-week high of $33.63. The company has a market capitalization of $1.04 billion, a P/E ratio of -10.79 and a beta of 1.20. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.58. The stock has a 50-day moving average price of $9.55 and a 200-day moving average price of $12.81.

Evolent Health (NYSE:EVH - Get Free Report) last announced its earnings results on Thursday, February 20th. The technology company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.38 by ($0.35). The business had revenue of $646.54 million for the quarter, compared to analyst estimates of $650.92 million. Evolent Health had a positive return on equity of 5.73% and a negative net margin of 2.41%. Analysts expect that Evolent Health, Inc. will post 0.08 EPS for the current year.

Insider Transactions at Evolent Health

In related news, CEO Seth Blackley acquired 55,225 shares of Evolent Health stock in a transaction dated Thursday, March 6th. The stock was acquired at an average price of $9.01 per share, for a total transaction of $497,577.25. Following the transaction, the chief executive officer now owns 762,217 shares of the company's stock, valued at $6,867,575.17. This represents a 7.81 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Brendan B. Springstubb acquired 5,000 shares of Evolent Health stock in a transaction on Tuesday, March 4th. The stock was purchased at an average price of $8.75 per share, with a total value of $43,750.00. Following the purchase, the director now owns 11,842 shares of the company's stock, valued at $103,617.50. The trade was a 73.08 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 74,000 shares of company stock worth $666,315. 1.60% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Truist Financial dropped their price target on shares of Evolent Health from $15.00 to $14.00 and set a "buy" rating for the company in a research report on Thursday, April 10th. Canaccord Genuity Group reduced their price objective on shares of Evolent Health from $23.00 to $16.00 and set a "buy" rating on the stock in a research note on Thursday, January 23rd. JMP Securities reissued a "market outperform" rating and issued a $12.00 price target on shares of Evolent Health in a research report on Friday, February 14th. JPMorgan Chase & Co. lowered their target price on shares of Evolent Health from $13.00 to $12.00 and set an "overweight" rating on the stock in a report on Monday, March 10th. Finally, Royal Bank of Canada cut their target price on Evolent Health from $20.00 to $17.00 and set an "outperform" rating for the company in a research note on Tuesday, January 14th. One equities research analyst has rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Evolent Health has an average rating of "Buy" and a consensus target price of $17.64.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.